Your browser doesn't support javascript.
Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London.
Russell, Beth; Moss, Charlotte L; Shah, Vallari; Ko, Thinzar Ko; Palmer, Kieran; Sylva, Rushan; George, Gincy; Monroy-Iglesias, Maria J; Patten, Piers; Ceesay, Muhammed Mansour; Benjamin, Reuben; Potter, Victoria; Pagliuca, Antonio; Papa, Sophie; Irshad, Sheeba; Ross, Paul; Spicer, James; Kordasti, Shahram; Crawley, Danielle; Wylie, Harriet; Cahill, Fidelma; Haire, Anna; Zaki, Kamarul; Sita-Lumsden, Ailsa; Josephs, Debra; Enting, Deborah; Swampillai, Angela; Sawyer, Elinor; D'Souza, Andrea; Gomberg, Simon; Harrison, Claire; Fields, Paul; Wrench, David; Rigg, Anne; Sullivan, Richard; Kulasekararaj, Austin; Dolly, Saoirse; Van Hemelrijck, Mieke.
  • Russell B; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. beth.russell@kcl.ac.uk.
  • Moss CL; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Shah V; Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
  • Ko TK; Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
  • Palmer K; King's College Hospital NHS Foundation Trust, London, UK.
  • Sylva R; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.
  • George G; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Monroy-Iglesias MJ; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Patten P; Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
  • Ceesay MM; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Benjamin R; Department of Haematological Medicine, Princess Royal University Hospital, Farnborough, UK.
  • Potter V; Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
  • Pagliuca A; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Papa S; Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
  • Irshad S; Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
  • Ross P; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Spicer J; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.
  • Kordasti S; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Crawley D; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.
  • Wylie H; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Cahill F; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.
  • Haire A; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.
  • Zaki K; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Sita-Lumsden A; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Josephs D; Haematology Department, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.
  • Enting D; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Swampillai A; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.
  • Sawyer E; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • D'Souza A; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Gomberg S; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Harrison C; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.
  • Fields P; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.
  • Wrench D; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Rigg A; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.
  • Sullivan R; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Kulasekararaj A; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.
  • Dolly S; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Van Hemelrijck M; Clinical Oncology, Guy's and St Thomas NHS Foundation Trust (GSTT), London, UK.
Br J Cancer ; 125(7): 939-947, 2021 09.
Article in English | MEDLINE | ID: covidwho-1360191
ABSTRACT

BACKGROUND:

Using an updated dataset with more patients and extended follow-up, we further established cancer patient characteristics associated with COVID-19 death.

METHODS:

Data on all cancer patients with a positive reverse transcription-polymerase chain reaction swab for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Guy's Cancer Centre and King's College Hospital between 29 February and 31 July 2020 was used. Cox proportional hazards regression was performed to identify which factors were associated with COVID-19 mortality.

RESULTS:

Three hundred and six SARS-CoV-2-positive cancer patients were included. Seventy-one had mild/moderate and 29% had severe COVID-19. Seventy-two patients died of COVID-19 (24%), of whom 35 died <7 days. Male sex [hazard ratio (HR) 1.97 (95% confidence interval (CI) 1.15-3.38)], Asian ethnicity [3.42 (1. 59-7.35)], haematological cancer [2.03 (1.16-3.56)] and a cancer diagnosis for >2-5 years [2.81 (1.41-5.59)] or ≥5 years were associated with an increased mortality. Age >60 years and raised C-reactive protein (CRP) were also associated with COVID-19 death. Haematological cancer, a longer-established cancer diagnosis, dyspnoea at diagnosis and raised CRP were indicative of early COVID-19-related death in cancer patients (<7 days from diagnosis).

CONCLUSIONS:

Findings further substantiate evidence for increased risk of COVID-19 mortality for male and Asian cancer patients, and those with haematological malignancies or a cancer diagnosis >2 years. These factors should be accounted for when making clinical decisions for cancer patients.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / SARS-CoV-2 / COVID-19 / Neoplasms Type of study: Etiology study / Prognostic study / Risk factors Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Br J Cancer Year: 2021 Document Type: Article Affiliation country: S41416-021-01500-z

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / SARS-CoV-2 / COVID-19 / Neoplasms Type of study: Etiology study / Prognostic study / Risk factors Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Br J Cancer Year: 2021 Document Type: Article Affiliation country: S41416-021-01500-z